
==== Front
J Immunother Cancer
J Immunother Cancer
jitc
jitc
Journal for Immunotherapy of Cancer
2051-1426
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39209456
10.1136/jitc-2024-009722
jitc-2024-009722
Commentary
2520
1506
Immune checkpoint blockade: timing is everything
https://twitter.com/FASinicropeMD
http://orcid.org/0000-0002-2907-1000
Sinicrope Frank A 1Sinicrope.Frank@mayo.edu

http://orcid.org/0000-0002-9612-8329
Turk Mary Jo 2Mary.jo.turk@dartmouth.edu

1 Division of Oncology, Mayo Clinic, Rochester, Minnesota, USA
2 Dartmouth Cancer Center and the Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, UK
DrFrank ASinicrope; Sinicrope.Frank@mayo.edu
FAS receives consulting fees from Hoffman LaRoche and Guardant Health. FAS has co-patent with Mayo Foundation for Medical Education and Research and Ventana Medical Systems, Inc. (US20210373024A1). MJT has no relevant disclosures.

2024
28 8 2024
12 8 e00972230 7 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

Neoadjuvant immunotherapy effectively uses the in situ tumor as a reservoir of tumor antigens to promote systemic antitumor immunity. Studies indicate that intratumoral responses to immune checkpoint inhibitors (ICIs) are mediated by resident memory T cells cells that are sequestered in tumors and have specificity for a wide range of tumor antigens. ICI treatment produces de novo priming of CD8+ T cells in tumor and in tumor-draining lymph nodes, and can boost the antitumor immune response by blocking inhibitory checkpoint proteins that can turn off T cells within the tumor. Neoadjuvant ICI treatment can enhance both intratumoral and systemic antitumor immunity, including expansion of intratumoral T-cell clones which is strongly associated with pathological treatment response. Recent data have shown high rates of pathological response to neoadjuvant immunotherapy with prolongation of survival compared with adjuvant ICI therapy alone in patients with unresectable or advanced melanoma. These data suggest that removal of the reservoir of tumor-specific T cells in the tumor and draining nodes by surgical resection may remove a significant proportion of the patient’s antitumor immunity with the potential to compromise ICI outcomes.

Immune Checkpoint Inhibitor
T cell
Neoadjuvant
Immunotherapy
http://dx.doi.org/10.13039/100011542 Center for Clinical and Translational Science, Mayo Clinic DERIVE http://dx.doi.org/10.13039/100005440 Center for Scientific Review R01CA225028 and R01CA254042
==== Body
pmc Entry of T cells into tumors appears to be a critical step in the development of an effective antitumor T-cell response that confers protection against recurrence and metastasis. Immune checkpoint inhibitors (ICIs) boost the immune response against cancer cells by blocking certain inhibitory molecules that can turn off T cells within the tumor.1 As an adjuvant treatment, ICIs have been shown to significantly improve clinical outcomes in patients with melanoma, non-small cell lung cancer (NSCLC), gastroesophageal cancer, urothelial cancer and renal cell carcinoma. Studies have evaluated neoadjuvant immunotherapy in locally advanced solid tumors in an effort to build on the success of ICIs in the adjuvant and/or advanced disease settings. In cancer treatment-naïve patients, neoadjuvant therapy is administered with the goal of downstaging tumors and improving their surgical resectability. Neoadjuvant immunotherapy effectively uses the in situ tumor as a reservoir of tumor antigens to promote systemic antitumor immunity. ICI treatment produces de novo priming of CD8+ T cells in tumor and in tumor-draining lymph nodes, and can boost the antitumor immune response by blocking inhibitory proteins that can turn off T cells within the tumor.1 Furthermore, neoadjuvant ICI treatment can enhance both intratumoral and systemic antitumor immunity, including expansion of intratumoral T-cell clones which are strongly associated with pathological treatment response.1 In patients with resectable NSCLC, neoadjuvant programmed cell death protein-1 (PD-1) blockade plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than did chemotherapy alone.2 Moreover, a study in patients with locally unresectable or metastatic melanoma showed that those who received neoadjuvant and adjuvant PD-1 blockade had a statistically significant prolongation of event-free survival compared with those who received adjuvant PD-1 blockade alone.3 Total exposure to ICI was similar in both groups in the intention-to-treat population and the overall immune-related adverse event rate was similar by study arm. Of note, there were some patients (less than 10%) in the neoadjuvant group who did not undergo surgery due to either a toxic effect or disease progression.3 These data establish that administration of an ICI prior to surgery has a beneficial impact on patient outcomes.

The adaptive immune response to cancer involves T-cell responses with an inherent capacity for memory of tumor antigens. Studies indicate that intratumoral responses to ICIs are mediated by resident memory T cells (TRM) cells that are sequestered in tumors and have specificity for a wide range of tumor antigens.4 TRM cells have emerged as an essential component of the immune response to cancer. TRM cells are long-lived, non-recirculating cells that are retained in tissue in the steady statetumor antigens.4 5 Studies indicate that tumor-specific T cells with a TRM phenotype are sequestered insolid tumors and in draining lymph nodes (LN) among patients with cancer.1 6 The TRM program can promote adhesion of CD8+ T cells in tumors making them less likely to egress and thereby, able to enhance the local response to ICI treatment.4 The TRM gene program can also induce T cell-mediated effector functions implicated in the recruitment of other immune cell types.1 Importantly, TRM cells in the tumor have been shown to be substantially increased by neoadjuvant ICI. TRM cells also have the potential to be mobilized into circulation and then to other locations during ICI treatment.4 Intratumoral TRM express several inhibitory receptors including PD-1 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and their accumulation is associated with response to ICIs as well as with better patient survival.5 In patients with oral cancer, TRM were found to be the predominant T-cell population responding to neoadjuvant ICI, shown using pretreatment and post-treatment datasets and integrated T-cell receptor (TCR) sequencing.1 Following neoadjuvant PD-1 blockade, neoantigen-specific T cells showed transcriptional elevation of TRM markers and inhibitory receptors in patients with melanoma7 as well as oral and lung cancers.1 8 Furthermore, TRM responsiveness to neoadjuvant ICI was characterized by gene programs related to activation, cytotoxicity, and effector functions.1

While TRM display proliferation signatures and undergo clonal expansion, a substantial fraction of tumor-infiltrating T cells failed to respond to neoadjuvant ICI by clonal expansion suggesting that some T cells in TRM clusters may be in an exhausted state.1 9 Markers of TRM include CD69 and CD103 of which the latter binds to E-cadherin expressed on epithelial cells and can enable exhausted CD8+ T cells to reside in tumor tissue.10 ICI treatment is believed to reverse an exhausted and dysfunctional state in T cells caused by chronic antigen exposure and characterized by the expression of inhibitory receptors including PD-1, CTLA4, lymphocyte-activation gene 3 (Lag-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).11 Our profiling of intratumoral T cells from patients with melanoma who were durable ICI responders point to heterogenous transcriptional states for TRM cells. One TRM cluster expressed TOX (thymocyte selection-associated HMG BOX) along with other markers of exhaustion, but another lacked TOX and exhibited high expression of interferon ϒ and other effector-associated transcripts.9 In addition to these inhibitory immune checkpoints, concurrent expression of CD38 with exhaustion markers was detected on CD8+ TRM within hepatocellular carcinoma, suggesting that CD38 can serve as a marker of T-cell exhaustion and as a potential therapeutic target for restoring cytotoxic CD8+ T-cell function.12 Inhibitory receptors are also upregulated during T-cell activation and are constitutively expressed by tissue-resident T cells, including treatment-responsive cells. ICI treatment in the neoantigen setting affords an opportunity to activate TRM cells residing within tumors to trigger an antitumor response. In patients with melanoma who experienced durable responses to immunotherapy, we found highly expanded, long-persisting TRM clonotypes in tumors with matched TRM counterparts in skin and in blood.9 These broadly-distributed TRM clonotypes were more likely to be enriched in clusters with transcriptional evidence of function.9 Among expanded TRM cell populations, multiple factors can influence antitumor T-cell responses that, in turn, influence patient outcomes. TRM cells may amplify the breath of cytotoxic CD8+ T-cell responses through dendritic cells, thereby strengthening antitumor immunity.13 However, TRM cells can be subject to regulation by regulatory T cells (Tregs) which may impair their longevity and/or induce a suppressed phenotype.14 Furthermore, TRM cells can be suppressed by loss of major histocompatibility complex-I expression as an immune escape mechanism that was not reversed by anti-PD-1 treatment.15 Another issue is the metabolic regulation of TRM cells that enables their persistence. TRM cells interact with tissue cells as part of an immune surveillance network and can encounter different metabolic environments. Instead of using glucose, TRM cells were shown to rely on fatty acid oxidation for their survival, and engage oxidative phosphorylation and glycolysis with the former being dependent on lipids.16 Unlike circulating memory T cells, TRM cells preferentially acquire fatty acids from their local environment, and studies show that programmed death-ligand 1 (PD-L1) blockade enables TRM cells to compete for fatty acids within the tumor microenvironment.16

T-cell populations can be primed against tumor-associated antigens in tumor-draining LNs that can then traffic through the circulation into the tumor. In tumor-containing LNs, TCR clones frequently overlap with those in primary tumor tissues suggesting that enrichment of tumor-reactive T cells in these nodes are a good source of T cells for immunotherapy. In addition to the differentiation of memory precursor cells into mature TRM cells in tissue, evidence suggests that circulating T cells can give rise to TRM cells within the lymphoid compartment. In this regard, TRM cells may egress from peripheral tissues including tumor-draining LNs into circulation and other peripheral sites, and potentially into the tumor.17 In a mouse model of melanoma where TRM populations were induced by neoadjuvant depletion of Tregs, TRM cells were shown to dominate in LNs where they afforded long-term protection against melanoma seeding whereas circulating memory T cells prevented melanoma growth in the lungs.18 Expanded TRM populations were also present in melanoma-involved LNs from patients, and their transcriptional signature predicted better survival.18 Thus, tumor-specific TRM cells persist in LNs where they can serve to restrict tumor metastasis. While it is yet to be determined if TRM cells can be mobilized from LNs, one could speculate that ICI treatment may also activate these populations. In preclinical models of colon cancer, immune activation was induced by ICI treatment predominantly in tumor-draining LNs whose resection at surgery was shown to abolish ICI-induced tumor regression.19 Similar consequences from resection of tumor-draining LNs in mouse models were seen in another study in early-stage but not advanced tumors. However, data also exist to indicate that LN metastasis may attenuate the tumor-specific CD8+ T-cell immune response and exacerbate immune suppression.20 Given that neoadjuvant ICI treatment in patients with intact tumors can enhance both local and systemic antitumor immunity, surgical removal of the reservoir of tumor-specific T cells in the tumor and potentially in tumor-draining LNs, may compromise the patient’s antitumor immunity directed at residual local and metastatic disease.

In summary, neoadjuvant immunotherapy effectively uses the in situ tumor as a reservoir of tumor antigens to promote systemic antitumor immunity and was shown to have a beneficial impact on patient survival.3 ICI treatment can cause de novo priming of CD8+ T cells in the primary tumor and in tumor-draining LNs. Activation of tumor-specific TRM cells by ICI treatment may promote their egress into circulation to suppress metastasis and improve patient survival. In this manner, neoadjuvant ICI treatment in patients with intact primary tumors can enhance both local and systemic antitumor immunity. Data suggest that removal of the reservoir of tumor-specific T cells in the tumor and draining LNs by initial surgical resection may remove a significant proportion of the patient’s antitumor immunity and thereby, compromise patient outcomes. While further study of the contribution of tumor-draining LNs, including those containing the tumor, to immunotherapy response and outcome in patients with solid tumors is awaited, existing data raise concern that initial surgical removal of the tumor prior to immunotherapy is counterproductive.

Funding: Grant support was received from Mayo Clinic DERIVE (to FAS) and NIH R01CA225028 and R01CA254042 (to MJT).

Patient consent for publication: Not applicable.

Ethics approval: Not applicable.

Provenance and peer review: Not commissioned; externally peer reviewed.
==== Refs
References

1 Luoma AM Suo S Wang Y et al Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy Cell 2022 185 2918 35 10.1016/j.cell.2022.06.018 35803260
2 Forde PM Spicer J Lu S et al Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer N Engl J Med 2022 386 1973 85 10.1056/NEJMoa2202170 35403841
3 Patel SP Othus M Chen Y et al Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma N Engl J Med 2023 388 813 23 10.1056/NEJMoa2211437 36856617
4 Ramirez DE Mohamed A Huang YH et al In the right place at the right time: tissue-resident memory T cells in immunity to cancer Curr Opin Immunol 2023 83 102338 10.1016/j.coi.2023.102338 37229984
5 Djenidi F Adam J Goubar A et al CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients J Immunol 2015 194 3475 86 10.4049/jimmunol.1402711 25725111
6 Sievers C Craveiro M Friedman J et al Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating Tcells following neoadjuvant immunotherapy in head and neck cancer Cancer Cell 2023 41 887 902 10.1016/j.ccell.2023.03.014 37059104
7 Oliveira G Stromhaug K Klaeger S et al Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma Nature New Biol 2021 596 119 25 10.1038/s41586-021-03704-y
8 Caushi JX Zhang J Ji Z et al Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Nat New Biol 2021 596 126 32 10.1038/s41586-021-03752-4
9 Han J Zhao Y Shirai K et al Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy Nat Cancer 2021 2 300 11 10.1038/s43018-021-00180-1 34179824
10 Kitakaze M Uemura M Hara T et al Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer Br J Cancer 2023 128 1828 37 10.1038/s41416-023-02202-4 36869093
11 Blank CU Haining WN Held W et al Defining T cell exhaustion Nat Rev Immunol 2019 19 665 74 31570879
12 Reolo MJY Otsuka M Seow JJW et al CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma Front Immunol 2023 14 1182016 10.3389/fimmu.2023.1182016 37377962
13 Menares E Gálvez-Cancino F Cáceres-Morgado P et al Tissue-resident memory CD8 T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells Nat Commun Sep 2019 10 4401 10.1038/s41467-019-12319-x
14 Abdeljaoued S Arfa S Kroemer M et al Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time J Immunother Cancer 2022 10 e003472 10.1136/jitc-2021-003472 35470231
15 Pizzolla A Keam SP Vergara IA et al Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment J Immunother Cancer 2022 10 e004574 10.1136/jitc-2022-004574 35550554
16 Lin R Zhang H Yuan Y et al Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma Cancer Immunol Res 2020 8 479 92 10.1158/2326-6066.CIR-19-0702 32075801
17 Rainey MA Allen CT Craveiro M Egress of resident memory T cells from tissue with neoadjuvant immunotherapy: Implications for systemic anti-tumor immunity Oral Oncol 2023 146 106570 10.1016/j.oraloncology.2023.106570 37738775
18 Molodtsov AK Khatwani N Vella JL et al Resident memory CD8+ Tcells in regional lymph nodes mediate immunity to metastatic melanoma Immunity 2021 54 2117 32 10.1016/j.immuni.2021.08.019 34525340
19 Fransen MF Schoonderwoerd M Knopf P et al Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy JCI Insight 2018 3 10.1172/jci.insight.124507
20 Delclaux I Ventre KS Jones D et al The tumor-draining lymph node as a reservoir for systemic immune surveillance Trends Cancer 2024 10 28 37 10.1016/j.trecan.2023.09.006 37863720
